EGFR and non-small cell lung carcinoma: Gefitinib has a high response rate and exhibits disease control in NSCLC patients with active EGFR mutations in the tumors; however, once first-line gefitinib therapy fails, tumor cells become resistant to gefitinib and discovery of the next appropriate regimen becomes very difficult.